Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 3,983 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Ventricular Dysfunction, Right, Hypoxia
Interventions: Hypoxia; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Meibomian Gland Dysfunction, Dry Eye
Interventions: LipiFlow System, Warm Compress Therapy + Lid Scrub; Device
Lead sponsor: TearScience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Laguna Hills, California • Miami, Florida + 6 more

Conditions: End Stage Renal Disease
Interventions: CoQ10, Placebo, HB-HIIT, Observational; Dietary Supplement · Drug · Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Nashville, Tennessee

Conditions: Congestive Heart Failure
Interventions: Carvedilol; Drug
Lead sponsor: Shaddy, Robert, M.D.; Individual
Eligibility: 1 Day to 17 Years
Enrollment: 75 participants
Timeline: 2002 – 2006
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more

Conditions: Ovarian Cancer, Sexual Dysfunction
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Cognitive Disorders, Personality Disorders
Interventions: Physical activity intervention with peer support (PA+PS), Physical activity intervention without peer support (PA); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Proteinuria
Interventions: Belatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Menopause, Aging
Interventions: KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mild Cognitive Impairment
Interventions: Intervention (videoconferencing); Other
Lead sponsor: University of Michigan; Other
Eligibility: 55 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pulmonary Embolism, Acute Pulmonary Embolism, Submassive Pulmonary Embolism, Massive Pulmonary Embolism
Interventions: FlowTriever System; Device
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Auburn, Alabama • Birmingham, Alabama • Los Angeles, California + 14 more

Conditions: Alzheimer Disease
Interventions: Donepezil, Vitamin E; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more

Conditions: Cognitive Impairment, Schizophrenia
Interventions: RL-007, RL-007 Matching Placebo; Drug
Lead sponsor: Recognify Life Sciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Blood Pressure, Endothelial Dysfunction
Interventions: Brief on-shift nap; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sexual Dysfunction
Interventions: Viveve System; Device
Lead sponsor: Michael Krychman, MD; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Alzheimer Disease
Interventions: sabirnetug, Placebo; Drug
Lead sponsor: Acumen Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Carlsbad, California • Fullerton, California • Irvine, California + 40 more

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson's Disease, Cognitive Impairment, Dementia
Interventions: Memantine, Placebo Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder, Voiding Disorders, Incontinence, Urinary
Interventions: parasacral transcutaneous electrical nerve stimulation (PTENS), Standard Urotherapy; Device · Other
Lead sponsor: University of Utah; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cognitive Impairment, Emergency Care, Dementia, Delirium
Interventions: PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan); Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: New Haven, Connecticut • Chicago, Illinois

Conditions: Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID, Long Covid19, Dyspnea, Orthostasis, Cognitive Impairment
Interventions: Comprehensive Rehabilitation, Augmented Usual Care; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo; Drug
Lead sponsor: Curacle Co., Ltd.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Impact of Hypoxia on Resting and Exertional Right Ventricular Performance

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

Sexual Functioning After Primary Treatment of Ovarian Cancer

Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

A Scalable Model for Promoting Functioning and Well-Being Among Older Adults With Mild Cognitive Impairment Via Meaningful Social Interactions: Project SPEAK!

Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis

FlowTriever Pulmonary Embolectomy Clinical Study

Memory Impairment Study (Mild Cognitive Impairment Study)

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

Night Shift Work, On-shift Napping, and Endothelial Function: A Pilot Study

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

ADRC Clinical Cohort (Alzheimer's Disease)

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

Pathway to Detection & Differentiation of Delirium & Dementia in the Emergency Department

Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers